NCT01441414 - PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2011

Primary Completion Date

March 27, 2014

Study Completion Date

March 27, 2014

Conditions

Metastatic Renal Cell Carcinoma

Interventions

BIOLOGICAL

PF-04856884

15 mg/kg/week intravenously \[IV\] until toxicity or disease progression

DRUG

Axitinib (AG-013736)

5 mg PO BID

DRUG

Axitinib (AG-013736)

5 mg PO BID

Trial Locations (29)

27704

Regional Cancer Care-Durham, Durham

65653

Masarykuv onkologicky ustav, Brno

68114

Nebraska Methodist Hospital, Omaha

75702

Texas Oncology-Tyler, Tyler

80012

Rocky Mountain Cancer Centers, Aurora

80112

Rocky Mountain Cancer Centers, Centennial

80124

Rocky Mountain Cancer Centers, Lone Tree

80138

Rocky Mountain Cancer Centers, Parker

80218

Rocky Mountain Cancer Centers, Denver

80220

Rocky Mountain Cancer Centers, Denver

80228

Rocky Mountain Cancer Centers, Lakewood

80260

Rocky Mountain Cancer Centers, Thornton

80303

Rocky Mountain Cancer Centers, Boulder

80501

Rocky Mountain Cancer Centers, Longmont

80907

Rocky Mountain Cancer Centers, Colorado Springs

80909

Rocky Mountain Cancer Centers, Colorado Springs

81008

Rocky Mountain Cancer Centers, Pueblo

85258

Pinnacle Oncology Hematology, Scottsdale

85704

Arizona Oncology Associates, PC - HOPE, Tucson

85710

Arizona Oncology Associates, PC-HOPE, Tucson

89014

Comprehensive Cancer Centers of Nevada, Henderson

89052

Comprehensive Cancer Centers of Nevada, Henderson

89074

Comprehensive Cancer Centers of Nevada, Henderson

89128

Comprehensive Cancer Centers of Nevada, Las Vegas

89148

Comprehensive Cancer Centers of Nevada, Las Vegas

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

98109

Seattle Cancer Care Alliance, Seattle

98195

University of Washington Medical Center, Seattle

80120-4413

Rocky Mountain Cancer Centers, Littleton